RXRX

Recursion Pharmaceuticals, Inc. Class A Common Stock

4.47

USD

RXRX Earnings Reports

Positive Surprise Ratio

RXRX beat 11 of 18 last estimates.

61%

Next Report

Date of Next Report

Feb 26, 2026

Estimate for Q4 25 (Revenue/ EPS)

$25.08M

-$0.32

Implied change from Q3 25 (Revenue/ EPS)

+384.59%

-11.11%

Implied change from Q4 24 (Revenue/ EPS)

+455.92%

-39.62%

Recursion Pharmaceuticals, Inc. Class A Common Stock earnings per share and revenue

On Nov 05, 2025, RXRX reported earnings of -0.36 USD per share (EPS) for Q3 25, beating the estimate of -0.37 USD, resulting in a 4.61% surprise. Revenue reached 5.17 million, compared to an expected 17.32 million, with a -70.13% difference. The market reacted with a -0.80% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.32 USD, with revenue projected to reach 25.08 million USD, implying an decrease of -11.11% EPS, and increase of 384.59% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Nurix Therapeutics, Inc. Common stock

Report Date

Jan 28, 2026 For Q4 25

Estimate

-$0.88

Actual

-$0.82

Surprise

+7.66%

FAQ

What were Recursion Pharmaceuticals, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Recursion Pharmaceuticals, Inc. Class A Common Stock reported EPS of -$0.36, beating estimates by 4.61%, and revenue of $5.17M, -70.13% below expectations.

How did the market react to Recursion Pharmaceuticals, Inc. Class A Common Stock's Q3 2025 earnings?

The stock price moved down -0.8%, changed from $5.00 before the earnings release to $4.96 the day after.

When is Recursion Pharmaceuticals, Inc. Class A Common Stock expected to report next?

The next earning report is scheduled for Feb 26, 2026.

What are the forecasts for Recursion Pharmaceuticals, Inc. Class A Common Stock's next earnings report?

Based on 10 analysts, Recursion Pharmaceuticals, Inc. Class A Common Stock is expected to report EPS of -$0.32 and revenue of $25.08M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.